These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36952230)

  • 1. Characteristics, Treatment, and Outcomes of Real-World Talazoparib-Treated Patients With Germline BRCA-Mutated Advanced HER2-Negative Breast Cancer.
    Savill KMZ; Ivanova J; Asgarisabet P; Falkenstein A; Balanean A; Niyazov A; Ryan JC; Kish J; Gajra A; Mahtani RL
    Oncologist; 2023 May; 28(5):414-424. PubMed ID: 36952230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Outcomes, Treatment Patterns, and Health Resource Utilization Among Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutation: A Real-World Retrospective Study.
    Quek RGW; Mardekian J
    Adv Ther; 2019 Mar; 36(3):708-720. PubMed ID: 30656571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial.
    Litton JK; Hurvitz SA; Mina LA; Rugo HS; Lee KH; Gonçalves A; Diab S; Woodward N; Goodwin A; Yerushalmi R; Roché H; Im YH; Eiermann W; Quek RGW; Usari T; Lanzalone S; Czibere A; Blum JL; Martin M; Ettl J
    Ann Oncol; 2020 Nov; 31(11):1526-1535. PubMed ID: 32828825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of talazoparib for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the US.
    Pan J; Ren N; Ren L; Yang Y; Xu Q
    Sci Rep; 2024 Jun; 14(1):13935. PubMed ID: 38886516
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Petracci FE; Villarreal-Garza C; Argañaraz F; Abuin GG; Peñaloza J; Flores MA; Piazzoni L; Riggi C; Fabiano L; González L; Cieplinski B; Rivero S; Korbenfeld E; Mandó P
    Ecancermedicalscience; 2023; 17():1634. PubMed ID: 38414929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indirect treatment comparison of olaparib and talazoparib in germline BRCA-mutated HER2-negative metastatic breast cancer.
    McCrea C; Hettle R; Gulati P; Taneja A; Rajora P
    J Comp Eff Res; 2021 Sep; 10(13):1021-1030. PubMed ID: 34231369
    [No Abstract]   [Full Text] [Related]  

  • 7. Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial.
    Hurvitz SA; Gonçalves A; Rugo HS; Lee KH; Fehrenbacher L; Mina LA; Diab S; Blum JL; Chakrabarti J; Elmeliegy M; DeAnnuntis L; Gauthier E; Czibere A; Tudor IC; Quek RGW; Litton JK; Ettl J
    Oncologist; 2020 Mar; 25(3):e439-e450. PubMed ID: 32162822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study.
    O'Shaughnessy J; Brezden-Masley C; Cazzaniga M; Dalvi T; Walker G; Bennett J; Ohsumi S
    Breast Cancer Res; 2020 Oct; 22(1):114. PubMed ID: 33109210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in
    Wang J; Zhang Y; Yuan L; Ren L; Zhang Y; Qi X
    Aging (Albany NY); 2020 Nov; 13(1):450-459. PubMed ID: 33257598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of talazoparib in Japanese patients with germline BRCA-mutated locally advanced or metastatic breast cancer: results of the phase 1 dose-expansion study.
    Kotani H; Masuda N; Yamashita T; Naito Y; Taira T; Inoue K; Takahashi M; Yonemori K; Toyoizumi S; Mori Y; Nagasawa T; Hori N; Iwata H
    Breast Cancer; 2022 Nov; 29(6):1088-1098. PubMed ID: 35907135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Talazoparib Versus Chemotherapy in Patients with HER2-negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial.
    Lee KH; Sohn J; Goodwin A; Usari T; Lanzalone S; Im SA; Kim SB
    Cancer Res Treat; 2021 Oct; 53(4):1084-1095. PubMed ID: 33781053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world study of patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2‒Negative advanced breast cancer: Patient demographics, treatment patterns, adverse events, and physician-reported satisfaction in the United States, Europe, and Israel.
    Mahtani R; Niyazov A; Arondekar B; Lewis K; Rider A; Massey L; Lux MP
    Breast; 2022 Dec; 66():236-244. PubMed ID: 36368161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world clinical outcomes of patients with BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: a CancerLinQ® study.
    Miller RS; Mokiou S; Taylor A; Sun P; Baria K
    Breast Cancer Res Treat; 2022 May; 193(1):83-94. PubMed ID: 35194731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis.
    Gelmon KA; Fasching PA; Couch FJ; Balmaña J; Delaloge S; Labidi-Galy I; Bennett J; McCutcheon S; Walker G; O'Shaughnessy J;
    Eur J Cancer; 2021 Jul; 152():68-77. PubMed ID: 34087573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy.
    Rugo HS; Ettl J; Hurvitz SA; Gonçalves A; Lee KH; Fehrenbacher L; Mina LA; Diab S; Woodward NE; Yerushalmi R; Goodwin A; Blum JL; Martin M; Quek RGW; Tudor IC; Bhattacharyya H; Gauthier E; Litton JK; Eiermann W
    JNCI Cancer Spectr; 2020 Feb; 4(1):pkz085. PubMed ID: 32337496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of human epidermal growth factor receptor 2-negative metastatic breast cancer: Role of poly adenosine diphosphate (ADP-ribose) polymerase inhibitors.
    Vaid AK; Deshmukh C; Rohatgi N; Ghosh J
    Indian J Cancer; 2022 Mar; 59(Supplement):S130-S141. PubMed ID: 35343197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Talazoparib: First Global Approval.
    Hoy SM
    Drugs; 2018 Dec; 78(18):1939-1946. PubMed ID: 30506138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY.
    Balmaña J; Fasching PA; Couch FJ; Delaloge S; Labidi-Galy I; O'Shaughnessy J; Park YH; Eisen AF; You B; Bourgeois H; Gonçalves A; Kemp Z; Swampillai A; Jankowski T; Sohn JH; Poddubskaya E; Mukhametshina G; Aksoy S; Timcheva CV; Park-Simon TW; Antón-Torres A; John E; Baria K; Gibson I; Gelmon KA;
    Breast Cancer Res Treat; 2024 Apr; 204(2):237-248. PubMed ID: 38112922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment patterns, clinical outcomes, health resource utilization, and cost in patients with BRCA-mutated metastatic breast cancer treated in community oncology settings.
    Houts AC; Olufade T; Shenolikar R; Walker MS; Schwartzberg LS
    Cancer Treat Res Commun; 2019; 19():100121. PubMed ID: 30785027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline
    Litton JK; Scoggins ME; Hess KR; Adrada BE; Murthy RK; Damodaran S; DeSnyder SM; Brewster AM; Barcenas CH; Valero V; Whitman GJ; Schwartz-Gomez J; Mittendorf EA; Thompson AM; Helgason T; Ibrahim N; Piwnica-Worms H; Moulder SL; Arun BK
    J Clin Oncol; 2020 Feb; 38(5):388-394. PubMed ID: 31461380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.